Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

被引：28

作者：

Grothey, Axel

Sobrero, Alberto F.

Siena, Salvatore

Falcone, Alfredo

Ychou, Marc

Lenz, Heinz-Josef

Yoshino, Takayuki

Cihon, Frank

Wagner, Andrea

Van Cutsem, Eric

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Osped San Martino Genova, Genoa, Italy

[3] Osped Niguarda Ca Granda, Milan, Italy

[4] Univ Pisa, Pisa, Italy

[5] CRLC Val Aurelle, Montpellier, France

[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Bayer HealthCare Pharmaceut, Montville, NJ USA

[9] Bayer Pharma AG, Berlin, Germany

[10] Univ Hosp Gasthuisberg, Leuven, Belgium

来源：

关键词：

D O I：

10.1200/jco.2012.30.4_suppl.lba385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA385

引用

页数：2